Teikoku Seiyaku Co., Ltd. engages in the development, manufacture, and sale of medicated and medically related supplies. It offers a range of hot sensation, and analgesic and anti-inflammatory plasters. The company, through its subsidiaries, also engages in the research, development, and manufacture of pharmaceutical transdermal products; and production and sale of medical adhesive products and external aqueous gel preparations. Its transdermal products include Lidoderm, a prescription hydrogel patch for the treatment of post-herpetic neuralgia; IontoPatch, an extended time-released electronic transdermal drug delivery system; Envela, a dressing for use in the management of psoriasis and the...
Founded in 1848
Noven Pharmaceuticals, Inc. Announces Settlement of Lidoderm(R) Patent Litigation with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc
Apr 16 14
Noven Pharmaceuticals, Inc. announced that it has entered into an agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to Noven's lidocaine topical patch 5% product. An Abbreviated New Drug Application for Noven's product is currently pending at the U.S. Food and Drug Administration (FDA). If approved, Noven's product would be a generic version of Endo's Lidoderm(R). The agreement allows Noven to launch its generic Lidoderm(R) product on or after March 1, 2015, if the product is approved by the FDA. The agreement provides for an earlier launch under certain circumstances. Pursuant to the agreement, the litigation on this matter, currently pending in U.S. District Court for the District of Delaware, will be dismissed. Other terms of the settlement were not disclosed. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.